市場調査レポート
商品コード
1283515

ヒトマイクロバイオームの世界市場:製品別 (薬剤、プロバイオティクス、プレバイオティクス)・用途別 (治療、診断)・疾患別 (がん、胃腸疾患、感染症)・種類別 (ペプチド、LBP、FMT) の将来予測 (2029年まで)

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 183 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.92円
ヒトマイクロバイオームの世界市場:製品別 (薬剤、プロバイオティクス、プレバイオティクス)・用途別 (治療、診断)・疾患別 (がん、胃腸疾患、感染症)・種類別 (ペプチド、LBP、FMT) の将来予測 (2029年まで)
出版日: 2023年05月26日
発行: MarketsandMarkets
ページ情報: 英文 183 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のヒトマイクロバイオームの市場規模は、2023年の3億米ドルから、2029年には17億米ドルに達し、予測期間中に36.1%のCAGRで成長すると予測されています。

ヒトマイクロバイオーム市場の成長を促進する主な要因は、個別化医療に対する需要の急増であり、自然でホリスティックなアプローチに対する需要の高まりが市場の成長を促進すると期待されています。しかし、微生物の相互作用に関する理解は限られているため、市場の成長はある程度抑制されると予想されます。

"用途別では、治療分野がヒトマイクロバイオーム市場で最大のシェアを占める"

用途別に見ると、マイクロバイオームが人間の健康維持に果たす重要な役割に対する理解の高まりにより、治療分野が2023年に市場を独占しています。また、製薬企業やバイオテクノロジー企業からの投資拡大や、個別化医療への需要の高まりも、この市場を牽引しています。

"疾患別では、感染症分野がヒトマイクロバイオーム市場で最大のシェアを占める"

疾患別に見ると、2023年には感染症分野がより大きなシェアを占めています。この市場分野の成長は、ヒトの健康におけるマイクロバイオームの役割に対する理解が深まり、高度なシーケンス技術とバイオインフォマティクス技術の開発により、感染症の予防・治療のための新しいマイクロバイオームベースの治療薬の発見と特徴付けに道が開かれたことに起因していると考えられます。

"北米:ヒトマイクロバイオーム市場の最大シェア"

ヒトマイクロバイオーム市場で最大のシェアを占めたのは北米です。北米地域の大きなシェアは、この地域の医療・バイオテクノロジー産業が確立されており、高度なインフラ、最先端の研究機関、マイクロバイオーム研究に特化したバイオテクノロジー企業やCROの強力なエコシステムがあることに起因すると考えられます。北米には、マイクロバイオーム研究に特化したプログラムや専門知識を持つ一流の学術機関、研究病院、民間会社が存在し、ヒトマイクロバイオーム市場の成長に寄与しています。

"アジア太平洋":ヒトマイクロバイオーム市場で最も成長する地域"

アジア太平洋のヒトマイクロバイオーム市場は、予測期間中に最も高いCAGRで成長すると予測されています。これは、健康と病気におけるマイクロバイオームの重要性に対する認識の高まり、個別化医療に対する需要の高まり、シーケンス技術の進歩などに起因しています。アジア太平洋のヒトマイクロバイオーム市場のもう一つの主要な促進要因は、この地域の人口が多く、急速に高齢化が進んでいることです。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 技術分析
  • 顧客のビジネスに影響を与える動向/混乱
  • サプライチェーンとバリューチェーンの分析
  • エコシステム分析
  • ポーターのファイブフォース分析
  • 規制分析
  • 価格分析
  • 主な会議とイベント (2023年)
  • 主要な利害関係者と購入基準

第6章 ヒトマイクロバイオーム市場:用途別

  • イントロダクション
  • 治療
  • 診断

第7章 ヒトマイクロバイオーム市場:疾患別

  • イントロダクション
  • 感染症
  • 胃腸疾患
  • 内分泌疾患・代謝性疾患
  • がん
  • その他の疾患

第8章 ヒトマイクロバイオーム市場:製品別

  • イントロダクション
  • 薬剤
  • 診断検査
  • プロバイオティクス
  • プレバイオティクス
  • その他の製品

第9章 ヒトマイクロバイオーム市場:種類別

  • イントロダクション
  • 細菌連合体移植 (BCT)/糞便微生物叢移植 (FMT)
  • ペプチド
  • 生きた生物学的製剤 (LBP)
  • その他の種類

第10章 ヒトマイクロバイオーム市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋地域
  • その他の地域

第11章 競合情勢

  • イントロダクション
  • 企業が採用した主な戦略
  • 企業評価クアドラント
  • 企業評価クアドラント:スタートアップ/中小企業
  • 競合シナリオと動向

第12章 企業プロファイル

  • 主要企業
    • SERES THERAPEUTICS, INC.
    • ENTEROME
    • 4D PHARMA PLC
    • INTERNATIONAL FLAVORS & FRAGRANCES, INC.
    • OPTIBIOTIX HEALTH PLC
    • FERRING PHARMACEUTICALS
    • SYNLOGIC, INC.
    • SECOND GENOME INC.
    • VEDANTA BIOSCIENCES, INC.
    • YSOPIA BIOSCIENCE
    • FLIGHTPATH BIOSCIENCES, INC.
    • FINCH THERAPEUTICS GROUP, INC.
    • AOBIOME THERAPEUTICS
    • BIOGAIA
    • QUANTBIOME, INC. (DBA OMBRE)
  • その他の企業
    • VIOME LIFE SCIENCES, INC.
    • BIOHM HEALTH
    • DAYTWO
    • ALTAS BIOMED
    • BIONE VENTURES PRIVATE LIMITED
    • LUXIA SCIENTIFIC
    • METABIOMICS
    • SUN GENOMICS
    • SEED HEALTH
    • GNUBIOTICS SCIENCES

第13章 付録

目次
Product Code: BT 2711

The human microbiome market is projected to reach USD 1.7 billion by 2029 from USD 0.3 billion in 2023, at a CAGR of 36.1% during the forecast period. The key factors driving the growth of the human microbiome market are the surging demand for personalized medicine, and growing demand for natural and holistic approaches is expected to propel the growth of the market. However, limited understanding of microbial interactions are expected to restrain market growth to a certain extent.

The human microbiome market has been segmented based on product, type, application, disease, and region.

"By application, the therapeutics segment accounted for the largest share of the human microbiome market"

Based on application, the human microbiome market is categorized into therapeutics, and diagnostics. The therapeutics segment dominated the market in 2023, owing to the increasing understanding of the crucial role that the microbiome plays in maintaining human health. It is also driven by increasing investment from pharmaceutical and biotechnology companies and the growing demand for personalized medicine.

"By disease, infectious diseases segment accounted for the largest share in the human microbiome market"

Based on disease, the human microbiome market is segmented into infectious diseases, endocrine & metabolic disorders, gastrointestinal diseases, cancer, and other diseases. In 2023, the infectious diseases segment accounted for a larger share of the human microbiome market. Growth in this market segment can be attributed to increasing understanding of the role of the microbiome in human health and the development of advanced sequencing and bioinformatics techniques are paving the way for the discovery and characterization of novel microbiome-based therapeutics for the prevention and treatment of infectious diseases.

"North America: the largest share of the human microbiome market"

North America accounted for the largest share of the human microbiome market. The large share of the North America region can be attributed to a well-established healthcare and biotechnology industry in the region, with advanced infrastructure, cutting-edge research institutions, and a strong ecosystem of biotechnology companies and CROs specializing in microbiome research. The presence of top academic institutions, research hospitals, and private companies in North America with dedicated microbiome research programs and expertise has contributed to the growth of the human microbiome market.

"Asia Pacific: The fastest-growing region in the human microbiome market."

The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period. This is attributed to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. Another key driver for the Asia Pacific human microbiome market is the region's large and rapidly aging population.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 60% and Demand Side 40%
  • By Designation: Executives - 40%, Research Scientists- 30%, and Managers - 30%
  • By Country: North America- 22%, Europe- 42%, Asia Pacific- 11%, Rest of the World- 25%

Prominent Players

  • Seres Therapeutics, Inc. (US)
  • Enterome (France)
  • 4D pharma plc (UK)
  • International Flavors & Fragrances Inc. (US)
  • OptiBiotix Health Plc (UK)
  • Ferring Pharmaceuticals (Switzerland)
  • Synlogic, Inc. (US)
  • Second Genome, Inc. (US)
  • Vedanta Biosciences, Inc. (US)
  • YSOPIA Bioscience (France)
  • FlightPath Biosciences, Inc. (US)
  • Finch Therapeutics Group, Inc. (US)
  • AOBiome Therapeutics (US)
  • BioGaia (Sweden)
  • Quantbiome, Inc. (dba Ombre) (US)
  • Viome Life Sciences, Inc. (US)
  • BIOHM Health (US)
  • DayTwo (US)
  • Atlas Biomed (UK)
  • Bione Ventures Private Limited (India)
  • Luxia Scientific (France)
  • Metabiomics (US)
  • Sun Genomics (US)
  • Seed Health (US)
  • Gnubiotics Sciences (Switzerland)

Research Coverage:

This report provides a detailed picture of the human microbiome market. It aims at estimating the size and future growth potential of the market across different segments, such as the product (drugs, diagnostics tests, probiotics, prebiotics, and other products), application (therapeutic, and diagnostics), disease (infectious diseases, gastrointestinal diseases, endocrine & metabolic diseases, cancer, and other diseases), type (Bacterial consortia transplantation (BCT)/ fecal microbiota transplantation(FMT), peptides, live biotherapeutic products, and other types), and region (North America, Europe, Asia Pacific, and Rest of the World). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall human microbiome market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers"

  • Analysis of key drivers (collaborative efforts between microbiome industry and academia for microbiome research, surging demand for personalized medicine, and rising awareness about importance of human microbiome), restraints (adverse impact of complex regulatory policies on commercialization of microbiomes), opportunities (increased collaboration of key players and small innovative companies collaborating to work on new microbiome technologies, and advancements in sequencing and bioinformatics), and challenges (low patient adoption rate of microbiome-based therapies, and complexities involved in development of microbiome therapies) influencing the growth of the human microbiome market.
  • Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the human microbiome market.
  • Market Development: Comprehensive information about lucrative markets- the report analyses the human microbiome market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the human microbiome market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), and OptiBiotix Health Plc (UK) among others in the human microbiome market strategies. The report also helps stakeholders understand the pulse of the animal research model market and provides them information on key market drivers, restraints, challenges and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY
  • 1.6 RESEARCH LIMITATIONS
  • 1.7 STAKEHOLDERS
    • 1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 HUMAN MICROBIOME MARKET: RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
    • FIGURE 4 HUMAN MICROBIOME MARKET SIZE, 2023 (USD MILLION)
    • FIGURE 5 HUMAN MICROBIOME MARKET: FINAL CAGR PROJECTIONS (2023-2029)
    • FIGURE 6 HUMAN MICROBIOME MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.3 MARKET DATA ESTIMATION AND TRIANGULATION
    • 2.3.1 DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.4 INDUSTRY INSIGHTS
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 HUMAN MICROBIOME MARKET: GLOBAL RECESSION IMPACT
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)
    • FIGURE 9 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023 VS. 2029 (USD MILLION)
    • FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2023 VS. 2029 (USD MILLION)
    • FIGURE 11 HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 HUMAN MICROBIOME MARKET OVERVIEW
    • FIGURE 12 RISING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH
  • 4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION AND COUNTRY (2023)
    • FIGURE 13 THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
  • 4.3 HUMAN MICROBIOME MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
    • FIGURE 14 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Collaborative efforts between microbiome industry and academia for microbiome research
      • 5.2.1.2 Surging demand for personalized medicine
      • 5.2.1.3 Rising awareness about importance of human microbiome
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Adverse impact of complex regulatory policies on commercialization of microbiomes
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increased collaboration of key players and small innovative companies to work on new microbiome technologies
    • TABLE 5 EXAMPLES OF COMPANY DEVELOPMENT
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Slow patient adoption of microbiome-based therapies
      • 5.2.4.2 Complexities involved in development of microbiome therapies
  • 5.3 TECHNOLOGY ANALYSIS
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.5 SUPPLY AND VALUE CHAIN ANALYSIS
    • 5.5.1 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS
    • FIGURE 17 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS
    • 5.5.2 VALUE CHAIN ANALYSIS OF HUMAN MICROBIOME MARKET
    • FIGURE 18 HUMAN MICROBIOME MARKET: VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 19 HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS
  • 5.7 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 HUMAN MICROBIOME MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.7.1 THREAT OF NEW ENTRANTS
    • 5.7.2 THREAT OF SUBSTITUTES
    • 5.7.3 BARGAINING POWER OF BUYERS
    • 5.7.4 BARGAINING POWER OF SUPPLIERS
    • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 REGULATORY ANALYSIS
    • 5.8.1 FDA APPROVALS
    • 5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9 PRICING ANALYSIS
    • TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT
    • 5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS
  • 5.10 KEY CONFERENCES AND EVENTS IN 2023
    • 5.10.1 HUMAN MICROBIOME CONFERENCES (2023)
    • TABLE 12 HUMAN MICROBIOME CONFERENCES (2023)
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 20 HUMAN MICROBIOME MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
    • 5.11.2 HUMAN MICROBIOME MARKET: BUYING CRITERIA
    • FIGURE 21 KEY BUYING CRITERIA FOR HEALTH SUPPLEMENTS AND MEDICAL FOODS

6 HUMAN MICROBIOME MARKET, BY APPLICATION

  • 6.1 INTRODUCTION
    • TABLE 13 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • 6.2 THERAPEUTICS
    • 6.2.1 AVAILABILITY OF FUNDING FOR DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET
    • TABLE 14 HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 15 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 16 EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 17 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 6.3 DIAGNOSTICS
    • 6.3.1 INCREASE IN FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET
    • TABLE 18 HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 19 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 20 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 21 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2029 (USD MILLION)

7 HUMAN MICROBIOME MARKET, BY DISEASE

  • 7.1 INTRODUCTION
    • TABLE 22 HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
  • 7.2 INFECTIOUS DISEASES
    • 7.2.1 RISE IN CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO BOOST MARKET
    • TABLE 23 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
    • TABLE 24 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 25 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 26 EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.3 GASTROINTESTINAL DISEASES
    • 7.3.1 SPIKE IN CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO PROPEL MARKET
    • TABLE 28 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 29 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 30 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.4 ENDOCRINE & METABOLIC DISORDERS
    • 7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO BOOST MARKET
    • TABLE 32 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR ENDOCRINE & METABOLIC DISORDERS
    • TABLE 33 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 34 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 35 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.5 CANCER
    • 7.5.1 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR TREATMENT OF PELVIC AND COLON CANCER TO DRIVE MARKET
    • TABLE 37 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 38 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 39 EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 40 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.6 OTHER DISEASES
    • TABLE 41 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 42 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 43 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 44 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)

8 HUMAN MICROBIOME MARKET, BY PRODUCT

  • 8.1 INTRODUCTION
    • TABLE 45 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION))
  • 8.2 DRUGS
    • 8.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS TO DRIVE MARKET
    • TABLE 46 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 8.3 DIAGNOSTIC TESTS
    • 8.3.1 GROWING CONSUMER AWARENESS OF MICROBIOME-BASED TESTS TO BOOST MARKET
    • TABLE 50 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 51 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 52 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 8.4 PROBIOTICS
    • 8.4.1 GROWING RESEARCH ON PROBIOTICS TO PROMOTE CREDIBILITY IN HEALTH CLAIMS AND SAFETY
    • TABLE 54 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 55 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 56 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 8.5 PREBIOTICS
    • 8.5.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH
    • TABLE 58 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 59 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 60 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 61 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 8.6 OTHER PRODUCTS
    • TABLE 62 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 63 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 64 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)

9 HUMAN MICROBIOME MARKET, BY TYPE

  • 9.1 INTRODUCTION
    • TABLE 66 HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • 9.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)
    • 9.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH
    • TABLE 67 HUMAN MICROBIOME MARKET FOR BCT/FMT, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 69 EUROPE: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023-2029 (USD MILLION)
  • 9.3 PEPTIDES
    • 9.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO DRIVE MARKET
    • TABLE 71 HUMAN MICROBIOME MARKET FOR PEPTIDES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 72 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 73 EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 74 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 9.4 LIVE BIOTHERAPEUTIC PRODUCTS
    • 9.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET
    • TABLE 75 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 76 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 77 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 78 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 9.5 OTHER TYPES
    • TABLE 79 HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 80 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 81 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023-2029 (USD MILLION)

10 HUMAN MICROBIOME MARKET, BY REGION

  • 10.1 INTRODUCTION
    • FIGURE 22 HUMAN MICROBIOME MARKET, BY REGION, 2023 VS. 2029 (USD MILLION)
    • TABLE 83 HUMAN MICROBIOME MARKET, BY REGION, 2023-2029 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 23 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
    • TABLE 84 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 85 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 86 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 87 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Spike in research activities to drive market
    • TABLE 88 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 89 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 90 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 91 US: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Rising prevalence of chronic diseases to boost microbiome research
    • TABLE 92 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 93 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 94 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 95 CANADA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.2.3 NORTH AMERICA: RECESSION IMPACT
  • 10.3 EUROPE
    • TABLE 96 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 97 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 98 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 99 EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Rapid increase in government funding to propel market
    • TABLE 100 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 101 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 102 GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 103 GERMANY: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Significant government investments in genomics research to propel growth
    • TABLE 104 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 105 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 106 UK: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 107 UK: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Rise in microbiome sequencing startups to boost growth
    • TABLE 108 HUMAN MICROBIOME STARTUPS IN FRANCE
    • TABLE 109 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 110 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 111 FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 112 FRANCE: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.3.4 REST OF EUROPE
    • TABLE 113 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 114 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 115 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 116 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.3.5 EUROPE: IMPACT OF RECESSION
  • 10.4 ASIA PACIFIC
    • FIGURE 24 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
    • TABLE 117 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 118 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 120 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 121 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 Increasing R&D investments to drive growth
    • TABLE 122 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 123 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 124 CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 125 CHINA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Growing geriatric population to present opportunities for market growth
    • TABLE 126 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 127 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 128 JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 129 JAPAN: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Increasing prevalence of chronic diseases to support growth
    • TABLE 130 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 131 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 132 INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 133 INDIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 134 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 135 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 136 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 137 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.4.5 ASIA PACIFIC: RECESSION IMPACT
  • 10.5 REST OF THE WORLD
    • TABLE 138 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 139 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 140 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 141 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.5.1 REST OF THE WORLD: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY STRATEGIES ADOPTED BY PLAYERS
    • FIGURE 25 HUMAN MICROBIOME MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 COMPANY EVALUATION QUADRANT
    • FIGURE 26 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (2022)
    • 11.3.1 STARS
    • 11.3.2 EMERGING LEADERS
    • 11.3.3 PERVASIVE PLAYERS
    • 11.3.4 PARTICIPANTS
  • 11.4 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • 11.4.1 PROGRESSIVE COMPANIES
    • 11.4.2 STARTING BLOCKS
    • 11.4.3 RESPONSIVE COMPANIES
    • 11.4.4 DYNAMIC COMPANIES
    • FIGURE 27 HUMAN MICROBIOME MARKET: START-UPS/SMES EVALUATION QUADRANT (2022)
    • 11.4.5 COMPETITIVE BENCHMARKING
      • 11.4.5.1 Human microbiome market: Detailed list of start-ups/SMEs
    • TABLE 142 HUMAN MICROBIOME MARKET: DETAILED LIST OF START-UPS/SMES
      • 11.4.5.2 Human microbiome market: Competitive benchmarking of key players (start-ups/SMEs)
    • TABLE 143 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
  • 11.5 COMPETITIVE SCENARIO AND TRENDS
    • TABLE 144 HUMAN MICROBIOME MARKET: DEALS
    • 11.5.1 PRODUCT LAUNCHES
    • TABLE 145 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES
    • 11.5.2 EXPANSIONS
    • TABLE 146 HUMAN MICROBIOME MARKET: EXPANSIONS

12 COMPANY PROFILES

  • (Business overview, Products offered, Recent Developments, MNM view)**
  • 12.1 KEY PLAYERS
    • 12.1.1 SERES THERAPEUTICS, INC.
    • TABLE 147 SERES THERAPEUTICS, INC.: COMPANY OVERVIEW
    • 12.1.2 ENTEROME
    • TABLE 148 ENTEROME: COMPANY OVERVIEW
    • 12.1.3 4D PHARMA PLC
    • TABLE 149 4D PHARMA: COMPANY OVERVIEW
    • FIGURE 29 4D PHARMA: COMPANY SNAPSHOT (2022)
    • 12.1.4 INTERNATIONAL FLAVORS & FRAGRANCES, INC.
    • TABLE 150 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW
    • FIGURE 30 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2022)
    • 12.1.5 OPTIBIOTIX HEALTH PLC
    • TABLE 151 OPTIBIOTIX: COMPANY OVERVIEW
    • FIGURE 31 OPTIBIOTIX: COMPANY SNAPSHOT (2021)
    • 12.1.6 FERRING PHARMACEUTICALS
    • TABLE 152 FERRING PHARMACEUTICALS: COMPANY OVERVIEW
    • 12.1.7 SYNLOGIC, INC.
    • TABLE 153 SYNLOGIC, INC.: COMPANY OVERVIEW
    • FIGURE 32 SYNLOGIC, INC: COMPANY SNAPSHOT (2022)
    • 12.1.8 SECOND GENOME INC.
    • TABLE 154 SECOND GENOME INC.: COMPANY OVERVIEW
    • 12.1.9 VEDANTA BIOSCIENCES, INC.
    • TABLE 155 VEDANTA BIOSCIENCES: COMPANY OVERVIEW
    • 12.1.10 YSOPIA BIOSCIENCE
    • TABLE 156 YSOPIA BIOSCIENCE: COMPANY OVERVIEW
    • 12.1.11 FLIGHTPATH BIOSCIENCES, INC.
    • TABLE 157 FLIGHTPATH BIOSCIENCES, INC.: COMPANY OVERVIEW
    • 12.1.12 FINCH THERAPEUTICS GROUP, INC.
    • TABLE 158 FINCH THERAPEUTICS: COMPANY OVERVIEW
    • FIGURE 33 FINCH THERAPEUTICS: COMPANY SNAPSHOT (2022)
    • 12.1.13 AOBIOME THERAPEUTICS
    • TABLE 159 AOBIOME THERAPEUTICS: COMPANY OVERVIEW
    • 12.1.14 BIOGAIA
    • TABLE 160 BIOGAIA: COMPANY OVERVIEW
    • FIGURE 34 BIOGAIA: COMPANY SNAPSHOT (2021)
    • 12.1.15 QUANTBIOME, INC. (DBA OMBRE)
    • TABLE 161 QUANTBIOME, INC.: COMPANY OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 VIOME LIFE SCIENCES, INC.
    • 12.2.2 BIOHM HEALTH
    • 12.2.3 DAYTWO
    • 12.2.4 ALTAS BIOMED
    • 12.2.5 BIONE VENTURES PRIVATE LIMITED
    • 12.2.6 LUXIA SCIENTIFIC
    • 12.2.7 METABIOMICS
    • 12.2.8 SUN GENOMICS
    • 12.2.9 SEED HEALTH
    • 12.2.10 GNUBIOTICS SCIENCES
  • *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.2 CUSTOMIZATION OPTIONS
  • 13.3 RELATED REPORTS
  • 13.4 AUTHOR DETAILS